Tryptamine TherapeuticsEXOPF
13F holders, Q4 2024 (December 31)1holders
$0.02avg. 13F price*
At the end of Q4 2024, 1 institutions reported holding Tryptamine Therapeutics Ltd. (EXOPF) in their 13F filings. The largest holder was Financially Speaking Inc ($9K).
- Company
- Tryptamine Therapeutics Ltd.
- CUSIP
- Q9240A100
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024
No earlier quarter to compare with.
Ownership 1 holders
| Financially Speaking Inc | 0.01% | — | 361,600 | $9K |
"% of holder's portfolio" is EXOPF's weight in each manager's 13F, not the share of Tryptamine Therapeutics Ltd. the manager owns.